Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicenter, Open-Label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Next Previous
Trial Profile

A Phase III, Multicenter, Open-Label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obinutuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms GOYA
  • Sponsors Chugai; Nippon Shinyaku; Roche

Most Recent Events

  • 12 Dec 2023 Results assessing Molecular Determinants of Response to Mosunetuzumab Plus (R-CHOP) NCT01287741 and M-CHOP in NCT03677141 , in Patients with Diffuse Large B Cell Lymphoma , presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 09 Nov 2022 Results assessing Cost-Effectiveness and Cost-Utility Analyses of Polatuzumab Vedotin With Rituximab and Chemotherapy vs Rituximab and Chemotherapy in Treating Naive Diffuse Large B-Cell Lymphoma in Italy presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
  • 01 Aug 2022 Data from this study assessing baseline total metabolic tumor volume is prognostic for refractoriness to Immunochemotherapy in DLBCL published in the Clinical Lymphoma, Myeloma & Leukemia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top